A Phase II Study of Gemcitabine and Carboplatin Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer. San Antonio Breast Cancer Symposium Telli, M. L., Kurian, A. W., Jensen, K. C., et al 2011